FDA regulatory setbacks and Complete Response Letters

← Ideas · Themes

Multiple biopharma companies received FDA pushbacks in this period, including ACHV receiving a Complete Response Letter for its NDA due to manufacturing issues, and NPCE receiving a non-approvable letter for its NAUTILUS PMA-S requiring additional information. These setbacks contrast with prior expectations of near-term approvals and create significant uncertainty around commercialization timelines. The pattern underscores persistent FDA scrutiny of manufacturing quality and clinical evidence sufficiency.

Subscribe to this theme (RSS)